Shivamshree Businesses Limited (BOM:538520)
India · Delayed Price · Currency is INR 1.960
+0.090 (4.81%)
At close: Aug 1, 2025
Inozyme Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Revenue | 59.4 | 41.3 | 116.34 | 0.7 | 7.93 | 2.61 | Upgrade |
Revenue Growth (YoY) | -52.54% | -64.50% | 16520.29% | -91.17% | 203.60% | -72.25% | Upgrade |
Cost of Revenue | 36.99 | 30.8 | 80.55 | 0.25 | 3.41 | 2.23 | Upgrade |
Gross Profit | 22.41 | 10.51 | 35.79 | 0.45 | 4.52 | 0.38 | Upgrade |
Selling, General & Admin | 10.95 | 5.54 | 2.97 | 0.27 | 0.27 | 0.24 | Upgrade |
Other Operating Expenses | 19.12 | 13.57 | 33.07 | 0.68 | 0.76 | 0.6 | Upgrade |
Operating Expenses | 33.02 | 20.17 | 36.06 | 1.04 | 1.14 | 1.01 | Upgrade |
Operating Income | -10.61 | -9.67 | -0.27 | -0.58 | 3.37 | -0.62 | Upgrade |
Interest Expense | - | - | -0.18 | -0.27 | -0.34 | -0.32 | Upgrade |
Interest & Investment Income | - | - | 0.08 | 0.27 | 0.52 | 0.36 | Upgrade |
Currency Exchange Gain (Loss) | - | - | 0.53 | - | 0.11 | - | Upgrade |
Other Non Operating Income (Expenses) | 0.07 | 0.07 | 0.12 | -0 | -0 | 0.03 | Upgrade |
EBT Excluding Unusual Items | -10.54 | -9.6 | 0.28 | -0.59 | 3.66 | -0.55 | Upgrade |
Asset Writedown | - | - | - | - | - | 0 | Upgrade |
Pretax Income | -10.54 | -9.6 | 0.28 | -0.59 | 3.66 | -0.54 | Upgrade |
Income Tax Expense | 0.97 | -2.14 | 0.39 | -0.07 | 0.94 | -0.16 | Upgrade |
Net Income | -11.51 | -7.46 | -0.11 | -0.51 | 2.72 | -0.38 | Upgrade |
Net Income to Common | -11.51 | -7.46 | -0.11 | -0.51 | 2.72 | -0.38 | Upgrade |
Shares Outstanding (Basic) | 50 | 47 | 46 | 51 | 46 | 46 | Upgrade |
Shares Outstanding (Diluted) | 50 | 47 | 46 | 51 | 46 | 46 | Upgrade |
Shares Change (YoY) | -21.65% | 2.10% | -11.01% | 12.25% | - | -9.80% | Upgrade |
EPS (Basic) | -0.23 | -0.16 | -0.00 | -0.01 | 0.06 | -0.01 | Upgrade |
EPS (Diluted) | -0.23 | -0.16 | -0.00 | -0.01 | 0.06 | -0.01 | Upgrade |
Free Cash Flow | - | -6.45 | 0.28 | -0.5 | 0.57 | -2.29 | Upgrade |
Free Cash Flow Per Share | - | -0.14 | 0.01 | -0.01 | 0.01 | -0.05 | Upgrade |
Gross Margin | 37.73% | 25.44% | 30.77% | 64.71% | 56.98% | 14.59% | Upgrade |
Operating Margin | -17.86% | -23.41% | -0.23% | -83.14% | 42.55% | -23.90% | Upgrade |
Profit Margin | -19.37% | -18.05% | -0.09% | -73.29% | 34.27% | -14.67% | Upgrade |
Free Cash Flow Margin | - | -15.60% | 0.24% | -71.71% | 7.22% | -87.82% | Upgrade |
EBITDA | -9.29 | -8.61 | -0.24 | -0.5 | 3.49 | -0.46 | Upgrade |
EBITDA Margin | -15.63% | -20.84% | -0.21% | -71.86% | 44.00% | -17.50% | Upgrade |
D&A For EBITDA | 1.32 | 1.06 | 0.02 | 0.08 | 0.12 | 0.17 | Upgrade |
EBIT | -10.61 | -9.67 | -0.27 | -0.58 | 3.37 | -0.62 | Upgrade |
EBIT Margin | -17.86% | -23.41% | -0.23% | -83.14% | 42.55% | -23.90% | Upgrade |
Effective Tax Rate | - | - | 137.23% | - | 25.72% | - | Upgrade |
Revenue as Reported | 59.47 | 41.37 | 117.08 | 0.97 | 8.55 | 3.03 | Upgrade |
Advertising Expenses | - | - | 0.05 | 0.03 | 0.03 | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.